[go: up one dir, main page]

WO2023055244A1 - Pansement pour le traitement de plaies difficiles à cicatriser et procédé de fabrication de celui-ci - Google Patents

Pansement pour le traitement de plaies difficiles à cicatriser et procédé de fabrication de celui-ci Download PDF

Info

Publication number
WO2023055244A1
WO2023055244A1 PCT/PL2021/050068 PL2021050068W WO2023055244A1 WO 2023055244 A1 WO2023055244 A1 WO 2023055244A1 PL 2021050068 W PL2021050068 W PL 2021050068W WO 2023055244 A1 WO2023055244 A1 WO 2023055244A1
Authority
WO
WIPO (PCT)
Prior art keywords
dressing
cells
adscs
dressing material
dressings
Prior art date
Application number
PCT/PL2021/050068
Other languages
English (en)
Inventor
Małgorzata LEWANDOWSKA-SZUMIEŁ
Ilona SZABŁOWSKA-GADOMSKA
Stefan RUDZIŃSKI
Marta BOCHYŃSKA-CZYŻ
Tomasz GRZELA
Beata MROZIKIEWICZ-RAKOWSKA
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Priority to PCT/PL2021/050068 priority Critical patent/WO2023055244A1/fr
Priority to EP22793490.8A priority patent/EP4408490A1/fr
Priority to US18/697,489 priority patent/US20240407955A1/en
Priority to PCT/PL2022/050058 priority patent/WO2023055247A1/fr
Publication of WO2023055244A1 publication Critical patent/WO2023055244A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/34—Oils, fats, waxes or natural resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/01—Non-adhesive bandages or dressings
    • A61F13/01008—Non-adhesive bandages or dressings characterised by the material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/40—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing ingredients of undetermined constitution or reaction products thereof, e.g. plant or animal extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00089—Wound bandages
    • A61F2013/00272—Wound bandages protection of the body or articulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/64—Animal cells

Definitions

  • the invention concerns a dressing for treating hard-to-heal wounds and a process for the manufacture thereof, which may be useful in clinical practice, in particular for treating diabetic foot ulceration.
  • MSCs Mesenchymal stem cells
  • sources such as the bone marrow, adipose tissue, and cord blood
  • MSCs may be obtained from a number of sources, such as the bone marrow, adipose tissue, and cord blood, being a heterogenous population.
  • sources such as the bone marrow, adipose tissue, and cord blood
  • they also have a number of common features, such as an ability to undergo cell division, morphology similar to fibroblasts, ability to adhere to plastic, chondrogenic, osteogenic and adipogenic differentiation potential and presence of surface markers[1 , 2].
  • the main MSCs markers include CD73 (ecto- 5’-nucleotidase), CD90 (Thy-1) and CD105 (endoglin) [3], However, MSCs show no expression of hematopoietic cell markers, such as CD11b (integrin aM), CD14 (TLR4 coreceptor), CD34 (sialomucin), CD45 (protein tyrosine phosphatase receptor type C) and CD79a (membrane glycoprotein MB-1 ) [2].
  • CD11b integratedin aM
  • CD14 TLR4 coreceptor
  • CD34 sialomucin
  • CD45 protein tyrosine phosphatase receptor type C
  • CD79a membrane glycoprotein MB-1
  • the primary criterion used to differentiate MSCs from other cells is the simultaneous presence of CD105, CD73 and CD90 surface antigens with no expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 markers[3].
  • the stem cells found in the adipose tissue show a number of similarities to the MSCs from other tissues[4].
  • ADSCs also have immunomodulatory properties with an ability to differentiate into mesodermal cells: chondro-, osteo-, adipoblasts [2, 5], and also other specialized cells, such as skeletal muscle myoblasts [6] or even neurons[7, 8].
  • MSCs In terms of the future applications of MSCs, it is important that they are able to suppress inflammation. The effect may derive from blocked influx of inflammatory cells which would disrupt repair if they were retained and active in the tissue for too long.
  • An advantage of MSCs over topical administration of cytokines, for example, is the feedback between MSCs and other cells so that MSC signaling can adapt to the changing situation, such as suppression of inflammatory response in the first stage of regeneration and production of stimulators of cell proliferation and differentiation in the subsequent stage. Therefore, MSCs may have a positive effect on tissue regeneration even if they are not involved in the formation of the new repaired tissue by themselves. In addition, when stimulated by selected factors MSCs may increase their ability to improve tissue regeneration.
  • a massive advantage of MSCs is that they may be obtained from various sources at any stage of the patient’s life.
  • the adipose tissue and ADSCs that is, adipose-derived mesenchymal stem/stromal cells obtained from the tissue, have become a popular source of MSCs.
  • the advantage of ADSCs is availability and abundance in the adipose tissue, and they are relatively easy to obtain.
  • ADSCs typically do not require intensive proliferation in the laboratory to prepare the required quantity considered a therapeutic threshold. Owing to the wide availability of ADSCs, allogeneic therapies based on ADSCs are possible. Therefore, the therapeutic effect of ADSCs may be achieved owing to their differentiation ability, the immunomodulatory effect and ability to regulate processes in their vicinity by secreting appropriate cytokines and direct contact with other cells.
  • Mesenchymal stem cells are currently the most frequently used and uncontroversial source of cells used in rapidly developing regeneration medicine, with the adipose tissue being a particularly favorable source of these cells.
  • CUs Chronic ulcers
  • CUs are defined as disruption of tissues, mainly of the skin, that does not heal spontaneously or takes more than six weeks to heal.
  • CUs are a result of a complex cascade of pathogenetic factors and they are associated with a multitude of diverse medical conditions, including diabetes, vascular dysfunction, infections, and immobility/pressure (use of a wheel chair or long stay in bed).
  • An important common denominator of CUs is the presence of tissue ischemia.
  • CUs affect more than 1 % of the general population and up to 4% of people over the age of 80 years.
  • About 10% of patients affected by diabetes present CUs in the form of Diabetic Foot Ulcers (DFUs). These are chronic pedal wounds associated with infection, pain, skin discoloration, and occasional bleeding.
  • DFUs Diabetic Foot Ulcers
  • CUs result from combined angiopathy and neuropathy, causing reduced sensation in the affected tissue (Tahergorabi and Khazaei, 2012, Int J Prev Med, 3(12), 827-38).
  • CUs When unnoticed, trauma in the affected area without sufficient blood flow to ensure wound healing then provides an optimal milieu for injury and infection, resulting in chronic skin ulceration.
  • CUs may originate from skin burns, trauma, prolonged physical pressure or surgery.
  • the current treatments of CUs have limited efficacy, and they include wound dressings, topical use of growth factors, application of animal dermo-epidermic substitutes, exudate removal, hyperbaric oxygen therapy (Kessler, et al., 2003, Diabetes Care, 26(8), 2378-82) and debridement of necrotic tissues.
  • Adipose-Derived Stem Cells are a component of the human adipose tissue that produces large amounts of most of the factors needed for efficient wound healing.
  • ADSCs are easily isolated and expanded in culture through lipo-aspiration or fat sampling. ADSCs are classified based on the specific criteria from the International Federation of Adipose Therapeutics and Science (IFATS) (Bourin et al., 2013, Cytotherapy, 15(6), 641 -8) and they are currently one of the most studied cells for regenerative cell therapy applications (Si et al., 2019, Biomed. Pharmacother., 114: 108765).
  • IFATS International Federation of Adipose Therapeutics and Science
  • ADSCs are considered an encouraging treatment option for chronic wounds since numerous preclinical studies in animals demonstrated that ADSCs transplanted in the ulcer environment facilitate wound repair (Gdelkarim et al., 2018, Biomed. Pharmacother., 107, 625-633) through collagen/matrix secretion and deposition, growth factor secretion, angiogenesis and re- epithelization. Even though multiple intramuscular injections of ADSCs in liquid suspension might be a favorable therapeutic option in patients with DFU (Lee et al., 2012, Circ. J., 76(7), 1750-60; Bura et aL, 2014, Cytotherapy, 16(2), 245-57), their physical/temporal stability within the wound bed remains a critical issue to address. Indeed, it has been reported that injected ADSCs are locally unstable, display high motility and ultimately spread to sites far from the wound (Zhao et al., 2016, Cytotherapy, 18(7) 816-27).
  • Patent application WO 2016/209166 discloses a method for skin regeneration using stem cells deposited on a porous material as a result of their culturing in the presence of such a matrix.
  • Patent application EP3795184A1 discloses dressings in the form of bioresorbable foam made of collagen and/or gelatin impregnated with autologous ADSCs, intended for treating CDs, and in particular for skin regeneration and healing in patients with DFU.
  • the object of the invention is to provide a dressing useful for treating CU, in particular DFU, that would be suitable for long-term storage at low temperatures, would use the properties of ADSCs that facilitate wound healing and would not be limited to autologous applications. Such a dressing would enable easier and more widespread use in clinical practice.
  • a specific object of the invention is to provide a type of the dressing that would enable cell proliferation on the dressing, both during its preparation and also in conditions typical of the wound environment.
  • Another object of the invention is to provide a type of the dressing so that ADSC viability after the freezing process and subsequent storage at -80C (for at least 24 h) is at least 50%.
  • Another object of the invention is to provide a type of the dressing that simultaneously ensures ADSC migration from the dressing in the model wound environment.
  • at least 80% of the live ADSCs found in the dressing migrate to the wound environment compared to the pool of live cells after thawing.
  • Another object of the invention is to provide a type of the dressing that simultaneously ensures wound healing in the in vitro model represented by scratch closure assay.
  • the scratch area decreases by at least 80% 72 h after a test using the dressing.
  • the object of the invention is a dressing and a process for the manufacture thereof as specifically defined in the appended claims.
  • Fig. 1 shows cell proliferation determined using the Presto Blue assay that measures cell metabolic activity for ADSC cultures attached to / seeded on dressings. The results are expressed as means of several (at least three) technical replicates ⁇ SD (standard deviation).
  • Fig. 2 shows ADCS culture on dressings: a-d - Nikon TE2000-U light microscope images: a UrgoTul, b Vliweducation, c MepitelOne, d Mepilex. The narrow (blue) arrows indicate ADSCs found on the dressing. The thick (yellow) arrows indicate the dressing.
  • Fig. 3 shows images of dressings before freezing.
  • the arrows indicate sites of cell growth, a) MepitelOne before freezing, b) MepitelOne after thawing, c) UrgoTul before freezing, d) UrgoTul after thawing.
  • Fig. 4 shows images based on microscope observations after the dressings were applied on a model wound environment.
  • the narrow (blue) arrows indicate sites in which cells are still found on the dressing, the wide (yellow) arrows indicate sites in which cells spread from the dressing to the model wound environment which consists of fibrin glue mixed with a wound fluid, a-b - UrgoTul 3 days after the dressings were applied, c-d - MepitelOne 3 days after the dressings were applied, e-f - MepitelOne 7 days after the dressings were applied, g - UrgoTul 7 days after the dressings were applied, h - images of the MepitelOne dressing immediately after thawing and application on the model wound environment, day 1 , i - images of the MepitelOne dressing 3 days after thawing and application on the model environment, j - images of the MepitelOne dressing 7 days after thawing and application on the model environment, k - images of the glue
  • Fig. 5 shows: a) cell proliferation using the Presto Blue assay that measures metabolic activity of fibroblast cells (nHF) before and after the test.
  • the lower fluorescence intensity level for nHF+UrgoTul+ADSC is due to the fact that lower stiffness of UrgoTul dressing caused difficulties in management in in vitro cultures .
  • nHF+UrgoTul+ADSC fibroblast cells
  • the scratch closure rate control tests, nHF without the dressing; lowest rate, 20.33% of the original scratch area remained. The scratch closed most rapidly in the variant with ADSCs seeded on MepitelOne, wherein the surface was 100% closed after 72 h of observation; the scratch surface on the UrgoTul dressing decreased to 10.3% of the original area, respectively.
  • Example 1 Manufacture of dressings coated with ADSCs
  • the dressing material is cut into fragments that fit the culture vessel (e.g. 1 .2 cm x 1 .2 cm fragments are cut for a 24-well plate) and placed in a closed sterile container.
  • Fibronectin solution is prepared in a separate vessel by mixing fibronectin with DPBS w/o Ca, Mg at a 1 :100 ratio. The prepared solution is poured on the dressing material so that it is completely submerged in the fibronectin solution and placed at 37°C for incubation for 30-60 minutes. After the end of incubation, the fibronectin solution in which the dressing material was incubated is aspirated and washed with fresh DPBS.
  • Such a dressing material is transferred into a non-adherent plate (24-well plate) (one fragment per one well on the plate).
  • a silicone separator onto which the cell suspension will be applied dropwise, is placed on each dressing. Owing to the separator, the cell suspension is retained on the dressing material until the cells adhere to its surface.
  • ADSCs were thawed at 37°C and transferred to Falcon tubes with an appropriate growth medium.
  • the suspension was centrifuged at 5 min, 350 x g, 22°C. After centrifugation, the supernatant was removed and a fresh volume of the growth medium previously heated to 37°C was added to the remaining pellet; subsequently, their density was determined using an ADAM MC cell counter.
  • the optimum density of ADSCs seeded in a T75 bottle is 0.5-1.5 x 10 6 cells.
  • the incubation conditions were maintained at 37°C and 5% CO2.
  • the cells were cultured in a growth medium specific for the cells (XenoFree medium). The cultures were placed in an incubator and grown until confluence of approx.
  • the medium should be removed, and cells washed with DBPS w/o Ca, Mg previously heated to 37°C. After removing DPBS, Accutase heated to room temperature was poured on the cells. The culture vessel with Accutase was placed at 37°C for 5 minutes (incubation time with Accutase can be increased to 20 minutes, and the degree of cell detachment was tested every 3-5 minutes). To harvest the cells, an adequate volume of the growth medium is added to the culture vessel, pipetted several times and the whole culture suspension is collected into a sterile test tube. The cell suspension is centrifuged for 5 minutes at 350 x g, 22°C.
  • the supernatant is removed after centrifugation.
  • a fresh volume of the medium heated to 37°C is added to the cell pellet and pipetted several times to obtain homogeneous ceil suspension to be counted.
  • Cell density as counted should be between 1.25x10 6 -4.0x10 6 cells/mL. Cells between passages 2 and 4 were collected for subsequent stages.
  • the expanded cells prepared according to section 2 were applied on a previously prepared (see section 1 ) dressing material.
  • Optimum cell density for a dressing material fragment of 1.2 cm x 1 .2 cm is 2.5x10 5 per 200 pL.
  • a culture medium such as XenoFree should be used (cf. for example US20130136721 , W02015008275A1) for culturing human mesenchymal stem cells, such as for example Nutristem (Biological Industries Genos).
  • the culture vessel is placed at 37°C, 5% CO2 for at least 3 h so that the cells can settle on the dressing material.
  • the separators are removed from the dressings and the wells with the dressings are filled up with the medium to adequate volume according to the recommended specification for the culture vessel.
  • the dressings may be immobilized with weights.
  • Presto Blue is prepared in the medium for all wells at a 1 :10 ratio.
  • the cells are washed once with DPBS w/o Ca, Mg heated to 37°C.
  • An appropriate volume of the working solution of Presto Blue is added to a 0.5 mL well of a 24-well plate and incubated for 2 h at 37°C. After incubation, the medium from each well, such as 100 pL each, is transferred to a 96-well plate dedicated for fluorescence reading. Fluorescence was read at excitation parameters of 540 nm ( ⁇ 10 nm) and emission at 620 nm ( ⁇ 10 nm). A FLUOstar OPTIMA reader was used to measure fluorescence.
  • the dressings prepared using the materials listed in Table 1 were observed under the microscope (light microscope and electron microscope). The results are shown in Fig. 2.
  • the evaluation of ADSC viability and proliferation on the resulting dressings confirmed ADSC adhesion and proliferation on all the materials except for the Mepitel dressing material, and the dressing prepared using the material was excluded from further testing.
  • Selected dressings were rinsed with DPBS w/o Ca, Mg, and subsequently gently placed in a 2 mL cryotube using tweezers and a cryoprotectant was poured.
  • the cryotubes were placed in a deep freezer at -80°C for at least 24 h and subsequently transferred into a liquid nitrogen container.
  • the cryotubes were removed from the dewar/-80°C freezer and placed in a heating block at 37°C for 5 minutes. Subsequently, a fresh volume of the medium heated to 37°C was added to the cryotube.
  • the dressing was transferred to a sterile culture vessel filled with a fresh volume of the medium. The vessel was placed on a rocker with slight shaking for 5 minutes to remove any residual cryoprotectant. Subsequently, after removing the solution, a fresh volume of the culture medium was added to set up cultures or the dressings were used for further testing.
  • the dressings prepared using the Urgotul, MepitelOne and Mepilex materials were used for testing.
  • a series of microscope observations were conducted in the new cultures after thawing to evaluate the cell status. The results are shown in Fig. 3.
  • the blue arrows indicate sites of cell growth, a) MepitelOne before freezing, b) MepitelOne after thawing, c) UrgoTul before freezing, d) UrgoTul after thawing.
  • Example 4 ADSC migration test from dressings in a model wound environment.
  • fibrin glue mixed with a wound fluid obtained from 3 patients with diabetic wounds was used so that the total protein concentration in the final solution was equal in all tests.
  • the wound fluid was DPBS w/o Ca, Mg to which a specimen (scrapings) obtained during cleansing of a diabetic wound was collected.
  • Fig. 4 presents images based on microscope observations after the dressings were applied on the model wound environment.
  • the narrow arrows indicate sites in which cells are still found on the dressing, the thick arrows indicate sites in which cells diffused from the dressing to the - model wound environment which is consist of fibrin glue mixed with a wound fluid .
  • nHF cells were thawed at 37°C and transferred to Falcon tubes with an appropriate culture medium. The suspension was centrifuged at 5 min, 350 x g, 22°C. After centrifugation, the supernatant was removed and a fresh volume of the culture medium previously heated to 37°C was added to the remaining pellet; subsequently, their density was determined using an ADAM MC cell counter. The optimum density of nHF cells seeded in a T75 bottle is 0.3-0.8 x 10 6 cells. The incubation conditions were maintained at 37°C and 5% CO2. The cells were cultured In a culture medium specific for the cells.
  • Cultures were placed in an incubator and grown until the whole surface of the culture vessel was coated and then passaged or used for preparing an experiment. To this end, the medium should be removed, and cells washed with DBPS w/o Ca, Mg previously heated to 37°C. After removing DPBS, Accutase heated to room temperature is poured on the cells. The culture vessel with Accutase is placed at 37°C for 5 minutes (incubation time with Accutase can be increased to 20 minutes, and the degree of cell detachment is tested every 3-5 minutes). To harvest the cells, an adequate volume of the growth medium is added to the culture vessel, pipetted several times and the whole culture suspension is collected into a sterile test tube.
  • the cell suspension is centrifuged for 5 minutes at 350 x g, 22°C. The supernatant is removed after centrifugation. A fresh volume of the medium heated to 37°C is added to the cell pellet and pipetted several times to obtain homogeneous cell suspension to be counted.
  • Dual chamber inserts were placed on a 24-well plate to provide even spaces for closure.
  • Cells at a density of 1.5x10 4 cells/insert well were seeded in the spaces between the inserts.
  • the plate was placed in an incubator. The incubation conditions were maintained at 37°C and 5% CO2.
  • the cells were cultured in a DMEM Low Glucose growth medium with 10% FBS (fetal bovine serum) and 1% of an antibiotic mix (penicillin and streptomycin). The cells used in the experiments were between passages 1 and 4.
  • a Presto Blue assay was performed to evaluate/determine fibroblast cell metabolic activity. Subsequently, nHF cells and ADSCs on the dressings were stained with fluorescent dyes according to the manufacturer’s protocol, and the dressings with the cells were immediately placed on the fibroblasts.
  • the scratch assay is a laboratory technique used to analyze cell migration and cell-cell interactions. It is performed by creating a cell-free area e.g. by scratching a single cell layer or using inserts and recording
  • SUBSTITUTE SHEET (RULE 26) images of the scratch space at regular time intervals.
  • the scratch assay is dedicated for testing the migration potential of cells, such as e.g. fibroblasts that remodel and repair the connective tissue.
  • the percentage closure level for the free space was determined.
  • the free space is 100% at the initial stage. Any new cells that appear in the visual field confirm their migration and proliferation potential, which contributes to the percentage decrease of the space of the scratch being recorded.
  • the microscope images of scratch closure were recorded using a Nikon Ti automated fluorescence microscope in the inverted configuration with a cell incubation chamber which maintained adequate environmental parameters (37°C, 5% CO2).
  • the scratch area decreased to 10.3% after a 72 h test.
  • complete scratch closure was found after 72 h.
  • mesenchymal stem cells their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007;25:2739-2749.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne un pansement pour le traitement de plaies difficiles à cicatriser et un procédé de fabrication de celui-ci, pouvant être utile dans la pratique clinique, en particulier pour le traitement de l'ulcération du pied diabétique.
PCT/PL2021/050068 2021-09-30 2021-09-30 Pansement pour le traitement de plaies difficiles à cicatriser et procédé de fabrication de celui-ci WO2023055244A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
PCT/PL2021/050068 WO2023055244A1 (fr) 2021-09-30 2021-09-30 Pansement pour le traitement de plaies difficiles à cicatriser et procédé de fabrication de celui-ci
EP22793490.8A EP4408490A1 (fr) 2021-09-30 2022-09-30 Pansement pour le traitement de plaies difficiles à cicatriser et son procédé de fabrication
US18/697,489 US20240407955A1 (en) 2021-09-30 2022-09-30 Dressing for treating hard-to-heal wounds and a process for the manufacture thereof
PCT/PL2022/050058 WO2023055247A1 (fr) 2021-09-30 2022-09-30 Pansement pour le traitement de plaies difficiles à cicatriser et son procédé de fabrication

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/PL2021/050068 WO2023055244A1 (fr) 2021-09-30 2021-09-30 Pansement pour le traitement de plaies difficiles à cicatriser et procédé de fabrication de celui-ci

Publications (1)

Publication Number Publication Date
WO2023055244A1 true WO2023055244A1 (fr) 2023-04-06

Family

ID=78650031

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/PL2021/050068 WO2023055244A1 (fr) 2021-09-30 2021-09-30 Pansement pour le traitement de plaies difficiles à cicatriser et procédé de fabrication de celui-ci

Country Status (1)

Country Link
WO (1) WO2023055244A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118879625A (zh) * 2024-07-24 2024-11-01 南方医科大学珠江医院 一种硫化铜工程化干细胞外泌体的制备方法及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051722A1 (en) * 2014-01-10 2016-02-25 Anterogen Co., Ltd. Mesenchymal Stem Cell-Hydrogel-Biodegradable or Mesenchymal Stem Cell-Hydrogel-Undegradable Support Composition for Skin Regeneration or Wound Healing
US20180117217A1 (en) * 2016-04-12 2018-05-03 Anterogen Co., Ltd Mesenchymal stem cells-hydrogel-biodegradable or mesenchymal stem cells-hydrogel-nondegradable support composition for alleviating or improving epidermolysis bullosa

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051722A1 (en) * 2014-01-10 2016-02-25 Anterogen Co., Ltd. Mesenchymal Stem Cell-Hydrogel-Biodegradable or Mesenchymal Stem Cell-Hydrogel-Undegradable Support Composition for Skin Regeneration or Wound Healing
US20180117217A1 (en) * 2016-04-12 2018-05-03 Anterogen Co., Ltd Mesenchymal stem cells-hydrogel-biodegradable or mesenchymal stem cells-hydrogel-nondegradable support composition for alleviating or improving epidermolysis bullosa

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MOON KYUNG-CHUL ET AL: "Possibility of Injecting Adipose-Derived Stromal Vascular Fraction Cells to Accelerate Microcirculation in Ischemic Diabetic Feet: A Pilot Study", INTERNATIONAL JOURNAL OF STEM CELLS, vol. 12, no. 1, 30 March 2019 (2019-03-30), pages 107 - 113, XP055930705, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457712/pdf/ijsc-12-107.pdf> [retrieved on 20220613], DOI: 10.15283/ijsc18101 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118879625A (zh) * 2024-07-24 2024-11-01 南方医科大学珠江医院 一种硫化铜工程化干细胞外泌体的制备方法及其应用

Similar Documents

Publication Publication Date Title
JP4336821B2 (ja) 哺乳動物の骨髄細胞または臍帯血由来細胞と脂肪組織を利用した心筋細胞の誘導
Schneider et al. Long-term survival and characterisation of human umbilical cord-derived mesenchymal stem cells on dermal equivalents
KR102312720B1 (ko) 연조직 회복 및 재생을 위한 세포 재배치된 콜라겐 매트릭스
CA2645142C (fr) Cellules souches regulatrices
Zhou et al. The fabrication and evaluation of a potential biomaterial produced with stem cell sheet technology for future regenerative medicine
KR20100065338A (ko) 인간 또는 동물 배아에서 중간엽 줄기세포를 추출 및 그 분비물을 추출하는 방법
JP2016039806A (ja) サイトカイン産生細胞シートとその利用方法
Kakudo et al. Effects of transforming growth factor-beta1 on cell motility, collagen gel contraction, myofibroblastic differentiation, and extracellular matrix expression of human adipose-derived stem cell
Nair et al. Identification of p63+ keratinocyte progenitor cells in circulation and their matrix-directed differentiation to epithelial cells
Wu et al. Comparison of nucleus pulposus stem/progenitor cells isolated from degenerated intervertebral discs with umbilical cord derived mesenchymal stem cells
KR102155623B1 (ko) 성체 심장 줄기세포 군집
JPWO2015137419A1 (ja) 間葉系幹細胞の賦活化剤、賦活化された間葉系幹細胞およびその製造方法
Schneider et al. Three-dimensional epidermis-like growth of human mesenchymal stem cells on dermal equivalents: contribution to tissue organization by adaptation of myofibroblastic phenotype and function
Yang et al. Platelet poor plasma gel combined with amnion improves the therapeutic effects of human umbilical cord‑derived mesenchymal stem cells on wound healing in rats
Attiogbe et al. An in vitro autologous, vascularized, and immunocompetent Tissue Engineered Skin model obtained by the self-assembled approach
WO2023055244A1 (fr) Pansement pour le traitement de plaies difficiles à cicatriser et procédé de fabrication de celui-ci
EP3569693A1 (fr) Procédé de fabrication de culture cellulaire
US11395863B2 (en) Modification method for sheet-shaped cell culture
US20240407955A1 (en) Dressing for treating hard-to-heal wounds and a process for the manufacture thereof
CN108601799A (zh) 从年长细胞群中富集和扩增高潜能人间充质干细胞
Lee et al. Minimal cube explant provides optimal isolation condition of mesenchymal stem cells from umbilical cord
KR20240153589A (ko) 증폭 모낭 간엽계 세포의 제조 방법 및 그 사용
KR20080094431A (ko) 말초 혈액 유래 단핵 세포로부터 신경 전구 세포를 분리,배양 및 분화하는 방법
US20200109368A1 (en) Method for preparing differentiation-induced cells
US20230357724A1 (en) Human umbilical cord mesenchymal stem cell sheets and methods for their production

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21810153

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21810153

Country of ref document: EP

Kind code of ref document: A1